Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guangxin Xia

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
Acta Crystallographica. Section E, Structure Reports Online|May 19, 2011
(2R*,6S*)-tert-Butyl 2,6-bis-(hydroxy-meth-yl)morpholine-4-carboxyl-ateQian Chen, Bojun Li, Guangxin Xia
Acta Crystallographica. Section E, Structure Reports Online|July 15, 2011
(2R,6S)-tert-Butyl 2-(benzhydryl-carbamo-yl)-6-methyl-morpholine-4-carboxyl-ateHaiyang Wang, Guangxin Xia, Xuejun Liu, et al.
International Journal of Obesity (2005)|April 18, 2024
Association between BMI-based metabolic phenotypes and prevalence of intracranial atherosclerotic stenosis: a cross-sectional studyXue Xia, Xinsheng Han, Guangxin Xia, et al.
Acta Crystallographica. Section E, Structure Reports Online|May 19, 2011
(S)-tert-Butyl 3-(3-phenyl-1,2,4-oxa-diazol-5-yl)piperidine-1-carboxyl-ateLin Liu, Guangxin Xia, Xuejun Liu, et al.
Regulatory Toxicology and Pharmacology : RTP|October 5, 2019
Evaluation of preclinical safety profile of SPH3127, a direct renin inhibitor, after 28-day repeated oral administration in Sprague-Dawley rats and cynomolgus monkeysYu Mao, Leduo Zhang, Hua Li, et al.
European Journal of Drug Metabolism and Pharmacokinetics|September 9, 2019
The Nonclinical Pharmacokinetics and Prediction of Human Pharmacokinetics of SPH3127, a Novel Direct Renin InhibitorLeduo Zhang, Yu Mao, Zhiwei Gao, et al.
Bioorganic & Medicinal Chemistry|April 9, 2017
Erratum to "Discovery and optimization of a series of imidazo[4,5-b]pyrazine derivatives as highly potent and exquisitely selective inhibitors of the mesenchymal-epithelial transition factor (c-Met) protein kinase" [Bioorg. Med. Chem. 24 (2016) 4281-4290]Fei Zhao, Jing Zhang, Leduo Zhang, et al.
Clinical Therapeutics|March 3, 2021
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SPH3127: A Phase I, Randomized, Double-Blind, Placebo-Controlled TrialShan Jing, Ranchi Xu, Kexu Yang, et al.
Molecules (Basel, Switzerland)|January 23, 2013
A new triterpenoid from Teucrium viscidumXincai Hao, Jinwen Zhang, Guangxin Xia, et al.
Bioorganic & Medicinal Chemistry|July 25, 2016
Discovery and optimization of a series of imidazo[4,5-b]pyrazine derivatives as highly potent and exquisitely selective inhibitors of the mesenchymal-epithelial transition factor (c-Met) protein kinaseFei Zhao, Jing Zhang, Leduo Zhang, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Acta Crystallographica. Section E, Structure Reports Online|May 19, 2011
(2R*,6S*)-tert-Butyl 2,6-bis-(hydroxy-meth-yl)morpholine-4-carboxyl-ateQian Chen, Bojun Li, Guangxin Xia
Acta Crystallographica. Section E, Structure Reports Online|July 15, 2011
(2R,6S)-tert-Butyl 2-(benzhydryl-carbamo-yl)-6-methyl-morpholine-4-carboxyl-ateHaiyang Wang, Guangxin Xia, Xuejun Liu, et al.
International Journal of Obesity (2005)|April 18, 2024
Association between BMI-based metabolic phenotypes and prevalence of intracranial atherosclerotic stenosis: a cross-sectional studyXue Xia, Xinsheng Han, Guangxin Xia, et al.
Acta Crystallographica. Section E, Structure Reports Online|May 19, 2011
(S)-tert-Butyl 3-(3-phenyl-1,2,4-oxa-diazol-5-yl)piperidine-1-carboxyl-ateLin Liu, Guangxin Xia, Xuejun Liu, et al.
Regulatory Toxicology and Pharmacology : RTP|October 5, 2019
Evaluation of preclinical safety profile of SPH3127, a direct renin inhibitor, after 28-day repeated oral administration in Sprague-Dawley rats and cynomolgus monkeysYu Mao, Leduo Zhang, Hua Li, et al.
European Journal of Drug Metabolism and Pharmacokinetics|September 9, 2019
The Nonclinical Pharmacokinetics and Prediction of Human Pharmacokinetics of SPH3127, a Novel Direct Renin InhibitorLeduo Zhang, Yu Mao, Zhiwei Gao, et al.
Bioorganic & Medicinal Chemistry|April 9, 2017
Erratum to "Discovery and optimization of a series of imidazo[4,5-b]pyrazine derivatives as highly potent and exquisitely selective inhibitors of the mesenchymal-epithelial transition factor (c-Met) protein kinase" [Bioorg. Med. Chem. 24 (2016) 4281-4290]Fei Zhao, Jing Zhang, Leduo Zhang, et al.
Clinical Therapeutics|March 3, 2021
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SPH3127: A Phase I, Randomized, Double-Blind, Placebo-Controlled TrialShan Jing, Ranchi Xu, Kexu Yang, et al.
Molecules (Basel, Switzerland)|January 23, 2013
A new triterpenoid from Teucrium viscidumXincai Hao, Jinwen Zhang, Guangxin Xia, et al.
Bioorganic & Medicinal Chemistry|July 25, 2016
Discovery and optimization of a series of imidazo[4,5-b]pyrazine derivatives as highly potent and exquisitely selective inhibitors of the mesenchymal-epithelial transition factor (c-Met) protein kinaseFei Zhao, Jing Zhang, Leduo Zhang, et al.
Pageof 4